RFCA
IBRX icon

R&F Capital Advisors’s ImmunityBio IBRX Stock Holding History

R&F Capital Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$95K Buy
+26,726
New +$132K 0.02% 617

Other funds holding IBRX

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R&F Capital Advisors's IBRX Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in ImmunityBio (IBRX) in Q1 2017: 26,726 shares worth $95K. The stake represents 0.02% of the portfolio and ranks #617 among its holdings.

60 funds tracked by Wall St. Rank hold IBRX as of Q1 2017.

  • R&F Capital Advisors held 26,726 shares of ImmunityBio worth $95K as of Q1 2017.
  • ImmunityBio was a new R&F Capital Advisors position in Q1 2017.
  • ImmunityBio made up 0.02% of R&F Capital Advisors's portfolio in Q1 2017, its #617 holding.
  • 60 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.